Log In
Print this Print this

Xyntha, antihemophilic factor, moroctocog alfa (formerly ReFacto AF)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionRecombinant Factor VIII (rFVIII)
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationBleeding
Indication DetailsControl and prevent bleeding in patients with hemophilia; Treat and prevent bleeding in patients with hemophilia A
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today